Regular ArticleApoptosis May Be an Early Event of Progestin Therapy for Endometrial Hyperplasia
References (35)
Progestin therapy in endometrial hyperplasia
Gynecol Oncol
(1974)- et al.
Cytoplasmic progesterone and estradiol receptors in normal, hyperplastic, and carcinomatous endometria: therapeutic implications
Am J Obstet Gynecol
(1981) - et al.
Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40
Obstet Gynecol
(1997) Bcl-2 initiates a new category of oncogenes: regulators of cell death
Blood
(1992)- et al.
p53 and bcl-2 expression in endometrial adenocarcinoma. Comparison of serous and endometrioid subtypes (see comments)
Gynecol Oncol
(1996) - et al.
Down-regulation of bcl-2 is a potential marker of the efficacy of progestin therapy in the treatment of endometrial hyperplasia
Gynecol Oncol
(1999) - et al.
Apparent resistance in human endometrial carcinoma during combination treatment with tamoxifen and progestin may result from desensitization following downregulation of tumor progesterone receptor
Cancer Lett
(1992) - et al.
Proapoptotic effects of antiestrogens, progestins and androgen in breast cancer cells
J Steroid Biochem Mol Biol
(1999) - et al.
Bcl-2 expression in endometrial hyperplasia and carcinoma
Gynecol Oncol
(1996) - et al.
Changes in levels of mRNAs of transforming growth factor (TGF)-β1, -β2, -β3, TGF-β type II receptor and sulfated glycoprotein-2 during apoptosis of mouse uterine epithelium
J Steroid Biochem Mol Biol
(1996)
Long-term effect of megestrol acetate in the treatment of endometrial hyperplasia
Am J Obstet Gynecol
Progestin alone as primary treatment of endometrial carcinoma in premenopausal women
Cancer
The effects of progestational agents on hyperplasia and carcinoma in situ of the endometrium
Int J Gynaecol Obstet
Effects of hormone therapy on the endometrium
Mod Pathol
Female sex steroid receptors in normal, hyperplastic and carcinomatous endometrium. The relationship to serum steroid hormones and gonadotropins and changes during medroxyprogesterone acetate administration
Int J Cancer
Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium
N Engl J Med
Apoptosis: molecular mechanism for physiologic cell death
Clin Lab Sci
Cited by (55)
The impact of adjunctive metformin to progesterone for the treatment of non-atypical endometrial hyperplasia in a randomized fashion, a placebo-controlled, double blind clinical trial
2021, Journal of Gynecology Obstetrics and Human ReproductionCitation Excerpt :Progestins are the most commonly used medical therapy for EH since they inhibit the adverse effects of estrogen on the endometrium by decreasing estrogen and progesterone receptors and activating the progesterone receptors and hydroxylase enzymes to convert estradiol to estrone which is a weak and less active estrogen [5]. They also induce apoptosis in order to decrease glandular cellularityand also prevent angiogenesis in the myometrium [6,7]. Furthermore, evidence showed that insulin-resistance (IR) induced hyperinsulinemia has a specific role in histocyte canceration, especially in pathophysiologically changes of PCOS.
Uterine pathology in transmasculine persons on testosterone: a retrospective multicenter case series
2019, American Journal of Obstetrics and GynecologyCitation Excerpt :Progestin-based treatments and aromatase inhibitors are most commonly used.21 Progestin-based treatment acts directly on the progesterone receptors in the endometrium to arrest glandular proliferation and to decrease glandular cellularity by inducing apoptosis.22,23 In addition, the etonorgestrel implant or levonorgestrel intrauterine device provides excellent contraception for transmasculine persons, as spontaneous ovulation and pregnancy can occur.24,25
Dual-specificity phosphatase 6 predicts the sensitivity of progestin therapy for atypical endometrial hyperplasia
2015, Gynecologic OncologyCitation Excerpt :Many patients are initially responsive to progestin therapy. It has been reported that progestin-induced apoptosis occurs during the early period of treatment for endometrial hyperplasia [10]. However, the emergence of resistance is a major clinical problem [4].
Aromatase inhibitor "letrozole" versus progestin "norethisterone" in women with simple endometrial hyperplasia without atypia: A prospective cohort trial
2012, Middle East Fertility Society JournalCitation Excerpt :Endometrial hyperplasia is an estrogen-dependent disease which may present with abnormal uterine bleeding. Anti-estrogenic medications such as progestin and gonadotropin-releasing hormone agonists have been shown to reverse endometrial hyperplasia (2–7). Progestin appears to decrease glandular cellularity by triggering apoptosis.
Aberrant bcl-2 deficiency in endometrial hyperplasia
2011, PathologySite-specific <sup>68</sup>Ga-labeled Annexin A5 as a PET imaging agent for apoptosis
2011, Nuclear Medicine and BiologyCitation Excerpt :Anatomic imaging modalities such as magnetic resonance imaging (MRI) and computed tomography (CT) are less suitable for this purpose as they are based on tumor size reduction which occurs rather late after effective therapy and is not always conclusive [1]. Previous studies indicate that successful chemotherapy or radiotherapy induce apoptosis of neoplastic cells very early after therapy [2-4]. Therefore molecular imaging of apoptosis offers a direct and early measurement of response to cancer therapy [5,6].
- 1
To whom reprint requests should be addressed at Department of Pathology, Yale University School of Medicine, East Pavilion Room 2-607, 20 York Street, P.O. Box 208070, New Haven, CT 06520-8070. E-mail: [email protected].